Management of Ulcer-Like Dyspepsia
For patients with ulcer-like dyspepsia, test for H. pylori infection first and eradicate if positive, as this is the only intervention that can prevent subsequent peptic ulcer development in this specific subgroup. 1
Initial Diagnostic Approach
H. pylori Testing (Mandatory First Step)
- All patients with ulcer-like dyspepsia must undergo H. pylori testing using either invasive (endoscopic biopsy) or non-invasive methods (stool antigen, urea breath test), as this is the only therapy that can alter the natural history of the disease 2
- Do not treat empirically without testing—this leads to considerable overtreatment and should be avoided 2
- If H. pylori is positive, provide eradication therapy immediately 2, 3
When to Perform Endoscopy
- Perform esophagogastroduodenoscopy with biopsies in patients aged ≥55 years (some guidelines use ≥45 years as the threshold) 2, 3
- Endoscopy is mandatory if alarm symptoms are present (weight loss, dysphagia, persistent vomiting, evidence of GI bleeding, palpable mass) 2
- Consider endoscopy in patients with family history of gastroesophageal cancer or from high-risk geographic areas 2
- Endoscopy is indicated for treatment-resistant symptoms regardless of age 2
Treatment Algorithm
First-Line: H. pylori Eradication (If Positive)
- Bismuth quadruple therapy for 14 days is the preferred regimen when antibiotic susceptibility is unknown 4
- Alternative: Rifabutin triple therapy or potassium-competitive acid blocker dual therapy for 14 days in patients without penicillin allergy 4
- Critical evidence: Eradicating H. pylori prevents subsequent peptic ulcer development specifically in the ulcer-like dyspepsia subgroup (0% vs 16.7% ulcer development, p<0.05) 1
- However, H. pylori eradication does not significantly improve dyspeptic symptoms themselves (58% vs 55% symptom resolution compared to placebo) 1
Second-Line: Proton Pump Inhibitors
- If H. pylori is negative OR symptoms persist after successful eradication, initiate PPI therapy at standard dose (omeprazole 20-40 mg daily or lansoprazole 30 mg daily) for 4-6 weeks 2, 3, 5
- PPIs are superior to H2-receptor antagonists, antacids, and placebo for symptom relief 2
- Do not escalate to twice-daily PPI dosing empirically—higher doses are not more effective and should be avoided 6, 3
Third-Line: Tricyclic Antidepressants
- If symptoms persist after adequate PPI trial, initiate low-dose amitriptyline starting at 10 mg once daily, titrating slowly to 30-50 mg once daily 7, 2
- TCAs have moderate quality evidence for efficacy in refractory functional dyspepsia and target visceral hypersensitivity and pain pathways 7, 2
- Mirtazapine is supported for patients with weight loss 3
Post-Treatment Monitoring
Test-of-Cure
- Confirm H. pylori eradication with non-invasive testing (urea breath test or stool antigen) at least 4 weeks after completion of eradication therapy 4
- If eradication fails, use "optimized" bismuth quadruple therapy for 14 days if not previously used, or rifabutin triple therapy if BQT was the initial regimen 4
Endoscopy for Persistent Symptoms
- If symptoms persist after H. pylori eradication and 4-6 weeks of PPI therapy, perform endoscopy to exclude organic pathology 3, 5
Critical Pitfalls to Avoid
- Do not attribute symptoms to functional dyspepsia or IBS until bile reflux gastritis has been definitively excluded through endoscopy and histology 6
- Avoid opioids or surgery for refractory symptoms—these cause iatrogenic harm 2
- Do not routinely use prokinetics as first-line treatment; reserve for postprandial distress syndrome subtype if needed 3
- Avoid NSAIDs if currently being used—discontinue and reassess symptoms before proceeding with further evaluation 5
Lifestyle Modifications
- Recommend regular aerobic exercise, though evidence quality is very low 2
- Provide healthy general lifestyle advice, but avoid restrictive exclusion diets unless specific food triggers are identified 3